Purpose To explore the value of 18F-PSMA-1007 and 18F-FDG PET/CT in prostate cancer （PCa） patients, this study compared the performance of the two tracers to detect PCa and then analyzed the correlation between the metabolic parameters and serum PSA value. Finally, we evaluated the application of both tracers in the auxiliary staging of PCa patients. Methods Thirty patients diagnosed with PCa who underwent both 18F-PSMA-1007 and 18F-FDG PET/CT were enrolled. The detection rate, number, location of lesions, and metabolic parameters SUVs (SUVmax, SUVmean), PSMA-TV, MTV, TL-PSMA, TLG, and tumor-to-background ratio (TBR) were recorded and compared. The correlation between metabolic parameters and serum PSA was analyzed. Finally, the differences and consistency of both tracers for the same patient’s NM stage and clinical stage were compared. Results Patient analysis showed that 18F-PSMA-1007 PET/CT had a similar ability to identify the primary tumor and local recurrence (p=1.000) as 18F-FDG PET/CT but identified more patients with metastases (p=0.016), especially bone metastases (p=0.004). Lesion analysis showed that 18F-PSMA-1007 PET/CT identified more primary lesions, local recurrences, and metastases. It also had higher diagnostic efficacy for lymph nodes and bone metastases (both p<0.05). For lesions with positive uptake, the median SUVs and TBR of 18F-PSMA-1007 PET/CT were significantly higher than 18F-FDG PET/CT (all p<0.05). The median PSMA-TV was higher than the median MTV. Still, the difference was not statistically significant (p>0.05), while the median TL-PSMA was significantly higher than the median TLG (p<0.05). Volume-based metabolic parameters PSMA-TV, TL-PSMA, MTV, and TLG, were significantly and positively correlated with PSA (all p<0.05). In contrast, SUVs and TBR for the primary tumor or local recurrence were not associated with PSA. 18F-PSMA-1007 PET/CT identified more M1 patients and higher clinical stage, and it had higher diagnostic efficacy than 18F-FDG PET/CT (p<0.05). Conclusions 18F-PSMA-1007 PET/CT was a valuable imaging modality for PCa. It had better diagnostic efficacy, lesions detection, and a higher median value for metabolic parameters than 18F-FDG PET/CT. Volume-based metabolic parameters reflecting the total tumor burden were positively correlated with serum PSA levels. 18F-PSMA-1007 PET/CT had a higher clinical application value than 18F-FDG PET/CT for PCa patients.